These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 4133440)

  • 1. Letter: ICRF 159.
    Bellet RE; Mastrangelo MJ; Dixon LM
    Lancet; 1974 May; 1(7863):926. PubMed ID: 4133440
    [No Abstract]   [Full Text] [Related]  

  • 2. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 3. Potentially useful combinations of chemotherapy detected in mouse tumor systems.
    Kline I
    Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187
    [No Abstract]   [Full Text] [Related]  

  • 4. The enhanced therapeutic effect of cis-platinum (II) diamminodichloride against L1210 leukemia when combined with cyclophosphamide or 1,2-bis(3,5-dioxopiperazine-1-yl)propane or several other antitumor agents.
    Woodman RJ; Sirica AE; Gang M; Kline I; Venditti JM
    Chemotherapy; 1973; 18(3):169-83. PubMed ID: 4119363
    [No Abstract]   [Full Text] [Related]  

  • 5. Effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane on tumor blood vessels and its relationship to the antimetastatic effect in the Lewis lung carcinoma.
    James SE; Salsbury AJ
    Cancer Res; 1974 Apr; 34(4):839-42. PubMed ID: 4814996
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergism of ICRF 159 and radiotherapy in treatment of experimental tumors.
    Hellmann K; Murkin GE
    Cancer; 1974 Oct; 34(4):1033-9. PubMed ID: 4423775
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of fluoxidine on L1210 leukemia in mice.
    Pujman V; Sandberg J; Howsden L; Goldin A
    Neoplasma; 1970; 17(2):133-6. PubMed ID: 5425390
    [No Abstract]   [Full Text] [Related]  

  • 9. Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
    Tobias JS; Parker LM; Tattersall MH; Frei E
    Br J Cancer; 1975 Aug; 32(2):199-207. PubMed ID: 1212350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ICRF-159 in treatment of germinal testicular tumor in animals.
    Mount BM; Husk M
    Urology; 1974 Sep; 4(3):297-301. PubMed ID: 4472487
    [No Abstract]   [Full Text] [Related]  

  • 11. Antileukemic synergism between cyclophosphamide and an antitumor platinum compound.
    Walker EM; Gale GR
    Res Commun Chem Pathol Pharmacol; 1973 Sep; 6(2):419-25. PubMed ID: 4750093
    [No Abstract]   [Full Text] [Related]  

  • 12. Potentiating action of 5-fluorouracil when used in combination with platinium compounds and cyclophosphamide in treatment of advanced L1210 leukemia.
    Gale GR; Atkins LM; Schwartz P; Meischen SJ
    Bioinorg Chem; 1978; 8(5):445-51. PubMed ID: 687671
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Ethidium bromhydrate effect on L 1210 mouse leukemia].
    Gosse C; Le Pecq JB; Dechambre RP; Morizet J; Paoletti C
    C R Acad Hebd Seances Acad Sci D; 1974 Sep; 279(13):1127-9. PubMed ID: 4142937
    [No Abstract]   [Full Text] [Related]  

  • 14. Antileukemic properties of dichloro(1,2-diaminocyclohexane)platinum(II).
    Gale GR; Walker EM; Atkins LM; Smith AB; Meischen SJ
    Res Commun Chem Pathol Pharmacol; 1974 Mar; 7(3):529-38. PubMed ID: 4824827
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy of leukemia L1210 by 6-mercaptopurine (NSC-755) in combination with 6-methylthiopurine ribonucleoside (NSC-40774).
    Schabel FM; Laster WR; Skipper HE
    Cancer Chemother Rep; 1967 Jun; 51(3):111-24. PubMed ID: 6043734
    [No Abstract]   [Full Text] [Related]  

  • 16. Histological analysis of the antimetastatic effect of (plus or minus)-1,2-bis(3,5-dioxopiperazin-1-yl)propane.
    Salsbury AJ; Burrage K; Hellmann K
    Cancer Res; 1974 Apr; 34(4):843-9. PubMed ID: 4814997
    [No Abstract]   [Full Text] [Related]  

  • 17. Proceedings: Analysis of the antimetastatic action of the antimitotic agent ICRF 159.
    Hellmann K; James SE; Salsbury AJ
    Br J Cancer; 1974 Aug; 30(2):179. PubMed ID: 4419316
    [No Abstract]   [Full Text] [Related]  

  • 18. Adriamycin/cyclophosphamide combination chemotherapy: the importance of drug scheduling.
    Mulder JH; van Putten LM
    Eur J Cancer (1965); 1979 Dec; 15(12):1503-9. PubMed ID: 294960
    [No Abstract]   [Full Text] [Related]  

  • 19. Survival curve characteristics of drug-resistant murine leukemia.
    Johnson RE; Hardy WG
    Radiology; 1967 May; 88(5):988-92. PubMed ID: 6025057
    [No Abstract]   [Full Text] [Related]  

  • 20. A biochemical and pharmacological study of therapeutic synergism with 5-fluorouracil plus cyclophosphamide in murine L1210 leukemia.
    Fernandes DJ; Klubes P
    Cancer Res; 1979 Apr; 39(4):1396-404. PubMed ID: 421224
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.